Pulse Journal Club Active Debates Trending Explore Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Home Explore Journal Club Trending

⌘+K

Emerging CSF and Serum Biomarkers in Multiple Sclerosis | Synapse

April 26, 2026Open Access

Emerging CSF and Serum Biomarkers in Multiple Sclerosis

Key Points

To identify CSF and serum biomarkers that can predict relapse activity and disease severity in multiple sclerosis.
Assessment of biomarkers in cerebrospinal fluid (CSF) and serum samples.
Evaluation of CXCL13, CXCL9, IL-12b in CSF and GFAP, MOG in serum as predictors.
CSF CXCL13, CXCL9, and IL-12b are promising for predicting relapse activity.
Serum GFAP and MOG consistently indicate disease severity.

Abstract

CSF CXCL13, CXCL9, and IL-12b are promising biomarkers for predicting relapse activity, while serum GFAP and MOG appear to be consistent candidates for prognosticating disease severity.

Read Full Paperexternally

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Oechtering et al. (Thu,) studied this question.

synapsesocial.com/papers/69edab814a46254e215b3826 https://doi.org/https://doi.org/10.1212/nxi.0000000000200578

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy2017 · 1,644 citations
2Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course2010 · 265 citations
3New diagnostic criteria for multiple sclerosis: Guidelines for research protocols1983 · 7,405 citations
4Defining secondary progressive multiple sclerosis2016 · 417 citations
5Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis2024 · 12 citations